## VT104

Cat. No.:	HY-134956			
CAS No.:	2417718-25-1			
Molecular Formula:	C <sub>25</sub> H <sub>19</sub> F <sub>3</sub> N <sub>2</sub> O			
Molecular Weight:	420.43			
Target:	YAP			
Pathway:	Stem Cell/Wnt			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	6 months	
		-20°C	1 month	

®

MedChemExpress

### SOLVENT & SOLUBILITY

Preparing Stock Solutions		Solvent Mass Concentration	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.3785 mL	11.8926 mL	23.7852 mL
	5 mM	0.4757 mL	2.3785 mL	4.7570 mL	
	10 mM	0.2379 mL	1.1893 mL	2.3785 mL	

Diological Activity				
Description	VT104 is a potent and orally active YAP/TAZ inhibitor. VT104 prevents palmitoylation of endogenous TEAD1 and TEAD3 proteins. VT104 can be used in research of cancer <sup>[1][2]</sup> .			
In Vitro	VT104 (0-1000 nM) inhibits proliferation of NF2 mutant/defective cell line <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
In Vivo	VT104 (0.3-3 mg/kg; p.o.; NCI-H226-tumor bearing mice) blocks growth of NF2-deficient mesothelioma xenografts <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
	Animal Model:	NCI-H226-tumor bearing mice <sup>[1]</sup>		
	Dosage:	0.3, 1, and 3 mg/kg		
	Administration:	Oral administration		

# Product Data Sheet

|| 0 F F√|∕F Result:

### REFERENCES

[1]. Tang TT, et, al. Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma. Mol Cancer Ther. 2021 Jun;20(6):986-998.

[2]. Barry ER, et, al. Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine. Cells. 2021 Oct 11;10(10):2715.

#### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA